Appointed
Min Qiu
Chief Executive Officer
BYSI ·
BeyondSpring Inc.
Mr. Min Qiu, age 43, is appointed Chief Executive Officer of the Company, effective July 1, 2026.
Ready 8-Ks
22
Latest filing
October 6, 2026, 4:30 PM ET
Top materiality
0.80
Event mix
earnings ×7 · other_material ×4 · m_and_a ×3
Sentiment
9 pos · 2 neg · 11 neu
Latest earnings
reported 2025-Q3
Executive change
recent →
Recent 8-K filings for BYSI
Highest-materiality recent filing
BeyondSpring receives Nasdaq bid-price delisting notice; 180-day cure window to March 16, 2027
- Nasdaq notified BYSI on Sept 17, 2026 that bid price closed below $1.00 for 30 consecutive business days.
- Company has until March 16, 2027 to regain compliance by closing at >= $1.00 for 10 straight business days.
-
Closed Sept. 30, 2026 sale of all BeyondSpring Ltd. shares, which indirectly held Bulin and SEED Technology, to Biolin Investment Limited; no cash consideration was paid.
-
BeyondSpring gets Nasdaq notice as MVLS falls below $35M; 180 days to regain compliance
Nasdaq Listing Qualifications notified BeyondSpring on September 29, 2026 that market value of listed securities fell below $35 million for 30 consecutive business days, violating Rule 5550(b)(2).
-
BeyondSpring wins FDA Fast Track for Plinabulin in post-ICI NSCLC; sells China unit to fund DUBLIN-4
FDA granted Fast Track designation to Plinabulin plus docetaxel for 2L/3L advanced non-squamous NSCLC without actionable genomic alterations, post-ICI and platinum chemo.
-
BeyondSpring receives Nasdaq bid-price delisting notice; 180-day cure window to March 16, 2027
Nasdaq notified BYSI on Sept 17, 2026 that bid price closed below $1.00 for 30 consecutive business days.
-
BeyondSpring Q2 net loss $1.8M; ASCO data show 58% 24-month OS in post-ICI NSCLC
Q2 2026 net loss $1.8M vs $1.9M YoY; cash and short-term investments $6.5M at June 30, 2026.
-
BeyondSpring finalizes CEO Min Qiu compensation: $100K salary, 100K share options, severance terms
CEO Min Qiu receives $100K salary with 30% target bonus.
-
BeyondSpring CEO Lan Huang transitions to Chairman; Min Qiu named CEO effective July 1, 2026
Dr. Lan Huang steps down as CEO effective July 1, 2026; remains Chairman; forfeits all unvested equity awards.
-
Net loss from continuing operations $2.4M vs $2.6M YoY; discontinued ops loss $4.3M.
-
R&D expense $4.4M, G&A $4.6M; cash $12.6M as of Dec 31, 2025.
-
BeyondSpring delays second closings of SEED Therapeutics share sale to H1 2026
Second closings under Preferred Share Purchase Agreement for SEED Therapeutics Series A-1 shares postponed from Dec 2025 to H1 2026.
-
BeyondSpring raises $2.0M via registered direct offering of 800K shares at $2.50/share
Issued 800,000 ordinary shares to Ray Beauty Group Limited at $2.50/share, gross proceeds $2.0M.
-
BeyondSpring Q3 2025 net loss $1.7M; Plinabulin DCR 85% in NSCLC post-PD-1/L1
Net loss from continuing ops $1.7M vs $2.2M YoY; cash $12.5M up from $2.9M Dec 2024.
-
SEED Therapeutics closes $30M Series A-3, FDA clears IND for lead RBM39 degrader
Second close of $6M completes $30M Series A-3; BeyondSpring to own ~38.03% on as-converted basis.
-
BeyondSpring shareholders ratify CBIZ CPAs as auditor for FY2025
Shareholders ratified appointment of CBIZ CPAs P.C. as independent auditor for fiscal year ending Dec 31, 2025.
-
Q2 net loss narrows to $1.9M; Plinabulin shows 23% ORR in ICI-refractory cancers
Net loss from continuing operations $1.9M for Q2 2025 vs $2.7M in Q2 2024; cash $9.5M as of Jun 30, 2025 vs $2.9M Dec 2024.
-
BeyondSpring sets annual meeting for September 15, 2025; record date July 25
2025 annual meeting of shareholders scheduled for September 15, 2025.
-
Net loss from continuing ops $2.6M, up 24% YoY; R&D expense $0.9M, G&A $1.7M.
-
BeyondSpring replaces Marcum with CBIZ as auditor after Marcum's resignation
Marcum LLP resigned as independent auditor on April 8, 2025; CBIZ CPAs P.C. engaged April 9, 2025.
-
BeyondSpring FY2024 net loss $8.9M; Plinabulin Phase 3 shows OS benefit in NSCLC
Net loss from continuing ops $8.9M vs $14.0M in 2023; R&D expenses fell to $2.6M from $7.3M.
-
BeyondSpring closes first tranche of SEED Therapeutics stake sale for $7.4M; total deal $35.4M
First closing transferred 1,730,454 SEED Series A-1 Preferred Shares for $7,354,433 cash.
-
BeyondSpring sells SEED Therapeutics stake for $35.4M to fund Plinabulin trials
Sells 8,333,637 Series A-1 Preferred Shares at $4.25/share to three investors for ~$35.4M gross proceeds.
-
BeyondSpring changes SEC filing status to domestic issuer as of Jan 1, 2025
Effective Jan 1, 2025, BeyondSpring no longer qualifies as a foreign private issuer and will file domestic issuer forms.
Executive changes
Appointed
Na Li
Chief Financial Officer
BYSI ·
BeyondSpring Inc.
Ms. Na Li, age 49, is appointed Chief Financial Officer of the Company, effective July 1, 2026.
Appointed
Jiangwen Majeti
Vice Chair of the Board
BYSI ·
BeyondSpring Inc.
Dr. Jiangwen Majeti, the current Chair of the Nominating and Corporate Governance Committee of the Board and a member of the Compensation Committee of the Board, is appointed Vice Chair of the Board, effective July 1, 2026.
Role change
Lan Huang
Chair of the Board
BYSI ·
BeyondSpring Inc.
Dr. Lan Huang, the current Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, will transition from her role as Chief Executive Officer, effective July 1, 2026.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.65 · Most common event earnings